• Call +1.858.633.0165 or Fax +1.858.633.0166 or Contact Us

ENPP1 enzyme :: Ectonucleotide Pyrophosphatase, Phosphodiesterase 1 Enzyme

Scan QR to view Datasheet
Catalog # MBS653632
Unit / Price
  0.1 mg  /  $400 +1 FREE 8GB USB
ENPP1 enzyme
Product Name

Ectonucleotide Pyrophosphatase, Phosphodiesterase 1 (ENPP1), Enzyme

Popular Item
Also Known As

Ectonucleotide Pyrophosphatase, Phosphodiesterase 1 (ENPP1, PC1, Plasma Cell Membrane Glycoprotein) (Control Peptide)

Product Gene Name
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
Chromosome Location
Chromosome: 6; NC_000006.11 (132129156..132216295). Location: 6q22-q23
OMIM
125853
3D Structure
ModBase 3D Structure for P22413
Purity/Purification
Highly Purified
Form/Format
Supplied as a lyophilized powder from acetonitrile/H2O. Reconstitution: Reconstitute with 200ul sterile ddH2O
Concentration
~0.5 mg/ml (after reconstitution) (lot specific)
Source
Synthetic
Preparation and Storage
Lyophilized powder may be stored at -20°C. Stable for 6 months after receipt at -20°C. Stable for 6 months after receipt at -20°C. Reconstitute with sterile ddH2O. Aliquot to avoid repeated freezing and thawing. Store at -20°C. For maximum recovery of product, centrifuge the orginal vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.
Other Notes
Small volumes of ENPP1 enzyme vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
ENPP1 enzyme
C-KTHLPTFSQED, from the C Terminus of human ENPP1. Control peptide corresponding to polyclonal antibody, Catalog#MBS623475, goat x human.
Peptide Blocking:
Antibodies are typically supplied at 0.5mg/ml and peptides as a 100ug pellet. When peptides are reconstituted in 200ul water, the concentration will be 0.5mg/ml. To start, the best ratio would be 1:1 (which means molar excess of peptides relative to antibodies when identical volumes are mixed). Mix equal volumes of peptide and antibody at the required dilution and leave at ambient temperature. It is best is to have two identical blots, to be incubated with equal amount of antibodies, but one with the antibodies pre-adsorbed to the peptide for 20min. Then incubate and develop the two blots in parallel.
Applications Tested/Suitable for ENPP1 enzyme
Suitable for use in ELISA and Antibody blocking
Other applications not tested
Application Notes for ENPP1 enzyme
Optimal dilutions to be determined by the researcher
NCBI/Uniprot data below describe general gene information for ENPP1. It may not necessarily be applicable to this product.
NCBI GI #
NCBI GeneID
NCBI Accession #
NCBI GenBank Nucleotide #
UniProt Primary Accession #
UniProt Secondary Accession #
UniProt Related Accession #
NCBI Official Full Name
ectonucleotide pyrophosphatase/phosphodiesterase family member 1
NCBI Official Synonym Full Names
ectonucleotide pyrophosphatase/phosphodiesterase 1
NCBI Official Symbol
ENPP1  [Similar Products]
NCBI Official Synonym Symbols
M6S1; NPP1; NPPS; PC-1; PCA1; ARHR2; PDNP1
  [Similar Products]
NCBI Protein Information
ectonucleotide pyrophosphatase/phosphodiesterase family member 1; E-NPP 1; Ly-41 antigen; alkaline phosphodiesterase 1; plasma-cell membrane glycoprotein 1; plasma-cell membrane glycoprotein PC-1; membrane component chromosome 6 surface marker 1; phosphodiesterase I/nucleotide pyrophosphatase 1; membrane component, chromosome 6, surface marker 1
UniProt Protein Name
Ectonucleotide pyrophosphatase/phosphodiesterase family member 1
UniProt Synonym Protein Names
Membrane component chromosome 6 surface marker 1; Phosphodiesterase I/nucleotide pyrophosphatase 1; Plasma-cell membrane glycoprotein PC-1
UniProt Gene Name
ENPP1  [Similar Products]
UniProt Synonym Gene Names
M6S1; NPPS; PC1; PDNP1; E-NPP 1; NPPase  [Similar Products]
UniProt Entry Name
ENPP1_HUMAN
NCBI Summary for ENPP1
This gene is a member of the ecto-nucleotide pyrophosphatase/phosphodiesterase (ENPP) family. The encoded protein is a type II transmembrane glycoprotein comprising two identical disulfide-bonded subunits. This protein has broad specificity and cleaves a variety of substrates, including phosphodiester bonds of nucleotides and nucleotide sugars and pyrophosphate bonds of nucleotides and nucleotide sugars. This protein may function to hydrolyze nucleoside 5' triphosphates to their corresponding monophosphates and may also hydrolyze diadenosine polyphosphates. Mutations in this gene have been associated with 'idiopathic' infantile arterial calcification, ossification of the posterior longitudinal ligament of the spine (OPLL), and insulin resistance. [provided by RefSeq, Jul 2008]
UniProt Comments for ENPP1
Function: By generating PPi, plays a role in regulating pyrophosphate levels, and functions in bone mineralization and soft tissue calcification. PPi inhibits mineralization by binding to nascent hydroxyapatite (HA) crystals, thereby preventing further growth of these crystals. In vitro, has a broad specificity, hydrolyzing other nucleoside 5' triphosphates such as GTP, CTP, TTP and UTP to their corresponding monophosphates with release of pyrophosphate and diadenosine polyphosphates, and also 3',5'-cAMP to AMP. May also be involved in the regulation of the availability of nucleotide sugars in the endoplasmic reticulum and Golgi, and the regulation of purinergic signaling. Appears to modulate insulin sensitivity. Ref.10

Catalytic activity: Hydrolytically removes 5'-nucleotides successively from the 3'-hydroxy termini of 3'-hydroxy-terminated oligonucleotides.A dinucleotide + H2O = 2 mononucleotides.

Cofactor: Binds 2 divalent metal cations per subunit

By similarity.

Enzyme regulation: At low concentrations of ATP, a phosphorylated intermediate is formed which inhibits further hydrolysis.

Subunit structure: The secreted form is monomeric

By similarity. Homodimer; disulfide-linked. Interacts with INSR. Ref.10

Subcellular location: Cell membrane; Single-pass type II membrane protein. Basolateral cell membrane; Single-pass type II membrane protein. Secreted

By similarity. Note: The proteolytically processed form is secreted

By similarity. Targeted to the basolateral membrane in polarized epithelial cells and in hepatocytes, and to matrix vesicles in osteoblasts. In bile duct cells and cancer cells, located to the apical cytoplasmic side. Ref.11 Ref.12

Tissue specificity: Expressed in plasma cells and also in a number of non-lymphoid tissues, including the distal convoluted tubule of the kidney, chondrocytes and epididymis. Ref.9

Domain: The di-leucine motif is required for basolateral targeting in epithelial cells, and for targeting to matrix vesicles derived from mineralizing cells

By similarity.

Post-translational modification: Autophosphorylated as part of the catalytic cycle of phosphodiesterase/pyrophosphatase activity.N-glycosylated.It has been suggested that the active SMB domain may be permitted considerable disulfide bond heterogeneity or variability, thus two alternate disulfide patterns based on 3D structures are described with 1 disulfide bond conserved in both.The interchain disulfide bonding resides in the transmembrane segment

By similarity.A secreted form is produced through cleavage at Lys-103 by intracellular processing

By similarity.

Involvement in disease: Ossification of the posterior longitudinal ligament of the spine (OPLL) [MIM:602475]: A calcification of the posterior longitudinal ligament of the spinal column, usually at the level of the cervical spine. Patients with OPLL frequently present with a severe myelopathy that can lead to tetraparesis.Note: The disease is caused by mutations affecting the gene represented in this entry. Ref.16Arterial calcification of infancy, generalized, 1 (GACI1) [MIM:208000]: A severe autosomal recessive disorder characterized by calcification of the internal elastic lamina of muscular arteries and stenosis due to myointimal proliferation. The disorder is often fatal within the first 6 months of life because of myocardial ischemia resulting in refractory heart failure.Note: The disease is caused by mutations affecting the gene represented in this entry. Ref.17 Ref.18 Ref.20 Ref.24Diabetes mellitus, non-insulin-dependent (NIDDM) [MIM:125853]: A multifactorial disorder of glucose homeostasis caused by a lack of sensitivity to the body's own insulin. Affected individuals usually have an obese body habitus and manifestations of a metabolic syndrome characterized by diabetes, insulin resistance, hypertension and hypertriglyceridemia. The disease results in long-term complications that affect the eyes, kidneys, nerves, and blood vessels.Note: Disease susceptibility is associated with variations affecting the gene represented in this entry. Ref.19Hypophosphatemic rickets, autosomal recessive, 2 (ARHR2) [MIM:613312]: A hereditary form of hypophosphatemic rickets, a disorder of proximal renal tubule function that causes phosphate loss, hypophosphatemia and skeletal deformities, including rickets and osteomalacia unresponsive to vitamin D. Symptoms are bone pain, fractures and growth abnormalities.Note: The disease is caused by mutations affecting the gene represented in this entry. Ref.21 Ref.22

Sequence similarities: Belongs to the nucleotide pyrophosphatase/phosphodiesterase family.Contains 2 SMB (somatomedin-B) domains.

Caution: It is uncertain whether Met-1 or Met-53 is the initiator.

Sequence caution: The sequence AAA63237.1 differs from that shown. Reason: Erroneous initiation. Translation N-terminally extended.The sequence AAH59375.2 differs from that shown. Reason: Erroneous initiation. Translation N-terminally extended.The sequence BAA02054.1 differs from that shown. Reason: Erroneous initiation. Translation N-terminally extended.
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
Products associated withENPP1 enzyme
Request a Quote

Please fill out the form below and our representative will get back to you shortly.

MBS000000
Contact Us

Please fill out the form below and our representative will get back to you shortly.

MBS000000